Dr. Benjamin N. Breyer

There's more usage of sort of big data sets, whether that's Medicare or MarketScan, employing epidemiology and clinical research techniques.

People across the world have gotten more sophisticated with access to data and software suites to analyze these things.

and more interest in the basic science of urethral stricture and also trials related to different therapeutics, which I think we're still lacking.

And I think that that's a growth area.

If we have time, I want to tell a quick story.

I think it was the San Diego AUA.

And I think I was a junior attending.

And walking out of the session, I saw Peter Carroll, who was my boss, my chair.

And he's been a very instrumental and close mentor for the past 25 years.

And I was pretty energized, thought, wow, this is really cool.

Like all these people together talking about science and Peter was walking and he was very disappointed in the quality of the science that he had just seen at the session.

And he was like, I, you know, I can't, you know, this is just where it feels like going anywhere.

You know, I think kind of with that lens of, I feel like we've come a long way, but we've also sort of not.

And I do think that there's a lot that recon in terms of sort of rigor, you know, I don't think that there's quite the same investment from grants and from industry that obviously cancer has the quality of the research that's being done in recon, you know, not to cause I do it, not to poo poo it, but.

It's definitely a step below cancer.

And I think there's a lot for us to get better at, there's a lot for us to kind of sink our teeth into other than, hey, look at this big data set that I analyzed and found this association, or this is a collaborative,

40 cases of this procedure works pretty well.

Like those things are incremental and I think helpful.

And I've done a bunch of that stuff, but we really got to get to the big questions.

And I think, you know, we can get into OptiLoom.